PSMA-binding agents and uses thereof
US10500292B2 · kind B2 · utility
6Cited by
2References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 8, 2018 |
| Grant date | Dec 10, 2019 |
| Priority date | — |
| Expiry date | Jan 8, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.